FierceBiotech |
Repurposing a GLP-1 diabetes drug to slow Parkinson's disease
FierceBiotech GLP-1 (glucagon-like peptide-1) receptor agonists make up a well-established class of treatment for Type 2 diabetes. AstraZeneca's Byetta and Bydureon, Novo Nordisk's Victoza and Ozempic, and Eli Lilly's Trulicity all belong to this family. Because of ... |
from diabetes - Google News
Social Plugin